{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:02:10Z","timestamp":1794272530856,"version":"4.9.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152741","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T22:25:08Z","timestamp":1746138308000},"page":"152741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"73","author":[{"given":"Alessandra Ida","family":"Celia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Maria","family":"Vescovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Iaconelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D\u2019Amario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6738-4836","authenticated-orcid":false,"given":"Andrea","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semarthrit.2025.152741_bib0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0002","first-page":"3618","volume":"43","author":"Humbert","year":"2022"},{"issue":"9921","key":"10.1016\/j.semarthrit.2025.152741_bib0003","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152741_bib0004","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","article-title":"Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve","volume":"383","author":"Guimar\u00e3es","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152741_bib0005","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152741_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252549","article-title":"Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus","volume":"16","author":"Kido","year":"2021","journal-title":"PloS one"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152741_bib0007","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0008","doi-asserted-by":"crossref","unstructured":"Arachchillage DJ, Platton S, Hickey K, et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2024.","DOI":"10.1111\/bjh.19635"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152741_bib0009","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0010","doi-asserted-by":"crossref","unstructured":"Celia AI, Galli M, Mancuso S, et al. Antiphospholipid Syndrome: insights into molecular mechanisms and clinical manifestations. 2024; 13(14): 4191.","DOI":"10.3390\/jcm13144191"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152741_bib0011","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.autrev.2011.04.011","article-title":"New autoantigens in the antiphospholipid syndrome","volume":"10","author":"Alessandri","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152741_bib0012","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152741_bib0013","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"The Lancet Haematology"},{"issue":"13","key":"10.1016\/j.semarthrit.2025.152741_bib0014","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152741_bib0015","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood advances"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0017","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0018","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed; 2019.","DOI":"10.1002\/9781119536604"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0019","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jrsm.6","article-title":"Graphical displays for meta-analysis: an overview with suggestions for practice","volume":"1","author":"Anzures-Cabrera","year":"2010","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-analysis: I(2) is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152741_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PloS one"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152741_bib0023","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152741_bib0024","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.3324\/haematol.2017.185132","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban","volume":"103","author":"Martinelli","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0025","doi-asserted-by":"crossref","unstructured":"Sato T, Nakamura H, Fujieda Y, et al. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study. 2019; 28(13): 1577\u201382.","DOI":"10.1177\/0961203319881200"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0026","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0961203319889156","article-title":"Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study","volume":"29","author":"Malec","year":"2020","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ejh.13770","article-title":"Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome","volume":"109","author":"Liu","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0028","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11239-021-02587-0","article-title":"Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome","volume":"54","author":"Williams","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0029","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/FJC.0000000000001578","article-title":"Apixaban versus vitamin K antagonists in patients with antiphospholipid syndrome: a cohort study","volume":"84","author":"Sikorska","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0030","doi-asserted-by":"crossref","unstructured":"Vardanyan SGK, Vardanyan V, Sargsyan S, Simonyan A. Lack of efficacy of rivaroxaban in the treatment of antiphospholipid syndrome and clinical significance of antiphospholipid antibodies. Ann Rheum Dis 2020.","DOI":"10.1136\/annrheumdis-2020-eular.3822"},{"issue":"21","key":"10.1016\/j.semarthrit.2025.152741_bib0031","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0032","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2015.10.105","article-title":"Antiphospholipid syndrome and anticoagulation quality: a clinical challenge","volume":"244","author":"Pastori","year":"2016","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152741_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001678","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis","volume":"7","author":"Koval","year":"2021","journal-title":"RMD open"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152741_bib0034","article-title":"Efficacy and safety of direct oral anticoagulants in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"14","author":"Gullapalli","year":"2022","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152741_bib0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/qjmed\/93.8.523","article-title":"Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome","volume":"93","author":"Tektonidou","year":"2000","journal-title":"QJM"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152741_bib0036","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41569-019-0314-y","article-title":"Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease","volume":"17","author":"Capodanno","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2023.2154651","article-title":"Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications","volume":"16","author":"Galli","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0038","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int J Med Sci"},{"issue":"18","key":"10.1016\/j.semarthrit.2025.152741_bib0039","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.1997.00440390101013","article-title":"A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis","volume":"157","author":"Krnic-Barrie","year":"1997","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152741_bib0040","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvac022","article-title":"Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy","volume":"8","author":"Galli","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152741_bib0041","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1055\/a-1730-8725","article-title":"Pharmacodynamic profiles of dual-pathway inhibition with or without Clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease","volume":"122","author":"Galli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152741_bib0042","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/jth.14936","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: a systematic review and meta-analysis","volume":"18","author":"Ortel","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"25","key":"10.1016\/j.semarthrit.2025.152741_bib0043","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood advances"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000131","article-title":"Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results","volume":"3","author":"Yelnik","year":"2016","journal-title":"Lupus Sci Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152741_bib0045","first-page":"2531","article-title":"Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus","volume":"29","author":"Somers","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152741_bib0046","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-024-02049-w","article-title":"Therapeutic potential of FXI inhibitors: hype or hope?","author":"Galli","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152741_bib0047","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FJC.0000000000001585","article-title":"Reevaluating anticoagulation in antiphospholipid syndrome: the role of Apixaban in the current treatment paradigm","volume":"84","author":"Galli","year":"2024","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722500112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722500112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T01:59:59Z","timestamp":1751594399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722500112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":47,"alternative-id":["S004901722500112X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152741","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152741"}}